secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIMEDX GROUP, INC. (MDXG)
CIK:        0001376339
Form:       8-K
Filed at:   2024-10-30T23:59:59+00:00
Accession:  0001193125-24-247640
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiMedx Q3 net sales $84M (+3% YoY); raises FY2024 growth outlook to high single-digits
--------------------------------------------------------------------------------

- GAAP net income $8.1M ($0.05 EPS); Adjusted EBITDA $18.2M (21.6% margin), up from $17.6M a year ago.
- Cash and cash equivalents $89M; net cash position $70M, up $20M sequentially.
- 2024 net sales growth guidance raised to high single-digits (from mid-to-high single-digits); Adjusted EBITDA margin expected above 20%.
- Q3 gross margin 81.8% vs 81.9% prior year; growth driven by AMNIOEFFECT, EPIEFFECT and HELIOGEN products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1376339/000119312524247640/0001193125-24-247640-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1376339/000119312524247640/d117946d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-247640

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer